Highlights of the Ninth Diabetes and Ramadan International Alliance conference (mena-zone virtual), January 21–22, 2021

The 9^th “Ramadan and Diabetes” international alliance annual conference was held over 2 days (January 21–22, 2021) virtually due to health restrictions imposed by the COVID-19 pandemic. The program included several sessions covering various aspects of Ramadan fasting from physiology, nutrition, pharmacotherapies, mental well-being, and bioethical considerations. A good proportion of the conference was used to highlight the 2021 edition of the International Diabetes Federation-diabetes and Ramadan (DaR) recommendations on diabetes management during Ramadan. The proposed new risk stratification tool for objectively assessing patient's risk was discussed. Results of the DAR global survey of the impact of COVID-19 on fasting practices were reported during the event. Results of a couple of recent trials were presented during the conference. The conference closed by a thoughtful review of the grading of evidence and a futuristic vision of future research directions. The present report provides a concise overview of the conference to help those who did not have the opportunity to attend the live event.

Key-words:

COVID-19 - diabetes - hyperglycemia - hypoglycemia - International Diabetes Federation-diabetes and Ramadan - Muslims - Ramadan fasting - safety

• References

• 1 Beshyah SA. Fasting during the month of Ramadan for people with diabetes: Medicine and Fiqh united at last. Ibnosina J Med Biomed Sci 2009;1:58-60.
• 2 Beshyah SA. IDF-DAR practical guidelines for management of diabetes during Ramadan. Ibnosina J Med Biomed Sci 2016;8:58-60.
• 3 Kenz S, Abusahmain H, Elmalti A, Beshyah SA. The 8th Diabetes and Ramadan International Alliance Conference: January 23–24, 2020, Dubai, United Arab Emirates. Ibnosina J Med Biomed Sci 2020;12:62-7.
• 4 Ghouri N, Hussain S, Ahmed SH, Beshyah SA, Rashid R, Al-Ozairi E, et al. Changing how we risk-categorize in Ramadan: Does the IDF-DAR scoring system achieve the requirements for people with diabetes internationally? Diabetes Res Clin Pract 2021:108835. [doi: 10.1016/j.diabres. 2021.108835].
• 5 Hassanein M, Sahay RK, Malek R, Shaltout I, Djaballah K, Demil N, et al. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: Results from wave 1 of the SOLIRAM study. J Endocr Soc 2021;5:A334.
• 6 Hassanein M, Akif Buyukbese M, Malek R, Pilorget V, Naqvi M, Berthou B, et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract 2020;166:108189.
• 7 Bajjaj H, Khan TA, Beshyah SA, Malik RA. Chapter 15 - Grading of evidence and areas of future research in diabetes and fasting during Ramadan. In Hassanein MM (Editor). Diabetes and Ramadan: Practical Guidelines 2021Publisher: International Diabetes Federation and the DAR International Alliance January 2021.